8-K
filed February 6, 2026, 6:59 PM ET
ticker LEXX
CIK 0001348362
other material
confidence high
sentiment negative
materiality 0.65
Lexaria Bioscience receives Nasdaq bid price deficiency notice; 180 days to cure
Lexaria Bioscience Corp.
- Received Nasdaq deficiency notice on Feb 4, 2026 for failing to meet $1.00 min bid price (Rule 5550(a)(2)).
- Compliance period runs 180 calendar days, until August 3, 2026, to regain compliance.
- To cure, closing bid price must be ≥$1.00 for at least 10 consecutive business days during period.
- If not cured, company may seek second 180-day period if it meets other initial listing standards.
- Failure to regain compliance could lead to delisting; company is evaluating options.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001640334-26-000230
- form_type
- 8-K
- ticker
- LEXX
- cik
- 0001348362
- company_name
- Lexaria Bioscience Corp.
- filed_at
- 2026-02-06T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:34.900231+00:00
- generated_at
- 2026-05-16T04:02:59.071319+00:00
- sec_items
- ["3.01"]
- event_type
- other_material
- sentiment
- negative
- materiality_score
- 0.65
- calibrated_materiality_score
- 0.65
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001640334-26-000230
- json_url
- https://secwatch.observer/filing/0001640334-26-000230.json
- markdown_url
- https://secwatch.observer/filing/0001640334-26-000230.md
- text_url
- https://secwatch.observer/filing/0001640334-26-000230.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1348362/000164033426000230/0001640334-26-000230-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1348362/000164033426000230/lxrp_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
TNON
Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity
Tenon Medical, Inc.
May 22, 2026, 5:15 PM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).
Comparable filing
May 21, 2026, Tenon Medical, Inc. (the “Company”)
received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying
the Company that it is no longer in compliance with the
Filing page
SEC filing
AGAE
AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K
Allied Gaming & Entertainment Inc.
May 21, 2026, 9:40 PM ET
other_material
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).
Comparable filing
May 19, 2026, All In FutureTech Alliance,
Inc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”)
from the Listing Qualifications Department (the “Staff”) of
Filing page
SEC filing
SNYR
Synergy CHC receives Nasdaq delisting notice for bid price below $1.00
Synergy CHC Corp.
May 18, 2026, 9:01 AM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).
Comparable filing
May 15, 2026, Synergy CHC Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of
The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the closing
Filing page
SEC filing
ISPC
iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance
iSpecimen Inc.
May 13, 2026, 5:00 PM ET
other_material
Items 1.01, 3.01, 3.02, 7.01, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).
Comparable filing
minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum
Bid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026
Filing page
SEC filing
HUMA
Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply
Humacyte, Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).
Comparable filing
May 4, 2026, Humacyte, Inc. (the “Company”)
received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification
that, for the 30 consecutive business days ended May 1, 2026, th
Filing page
SEC filing
GNLN
Greenlane regains Nasdaq compliance; BIC limits warrant conversion; board lock-up to April 2027
Greenlane Holdings, Inc.
April 27, 2026, 7:59 PM ET
other_material
Items 3.01, 7.01, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).
Comparable filing
March 25, 2026, Greenlane Holdings, Inc. (the “ Company ”) received a written notice
(the “ Notice ”) from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“ Nasdaq ”)
indicating that Nasdaq s
Filing page
SEC filing
ADTX
Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11
Aditxt, Inc.
May 29, 2026, 4:21 PM ET
other_material
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
This filing
a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).
Comparable filing
May 27, 2026, Aditxt, Inc. (the “Company”)
received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market
LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s
Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum
stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1)
(the “Stockholders’ Equity Requirement”). The Letter further
Filing page
SEC filing
LIMN
Liminatus Pharma receives Nasdaq delisting notice; appeals filed
Liminatus Pharma, Inc.
May 27, 2026, 4:30 PM ET
other_material
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
This filing
a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).
Comparable filing
May 20, 2026, the Company received a notice
from Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will
be delisted from The Nasdaq Global Mark
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.